Related Experiment Video

Updated: Jun 17, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

[Lapatinib treatment-option in trastuzumab-resistant breast cancer]

Béla Pikó1

  • 1Békés Megyei Képviselôtestület Pándy Kálmán Kórháza Megyei Onkológiai Központ 5700 Gyula Semmelweis u. 1. piko_bhome@freemail.hu

Magyar Onkologia
|January 15, 2010
PubMed

Insights

Lapatinib, a dual tyrosine kinase inhibitor, shows promise in treating HER2-positive breast cancer, particularly in advanced or metastatic cases. Clinical trials indicate improved disease progression times when combined with capecitabine.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • HER2 overexpression in 20-25% of breast cancers correlates with aggressive disease and poor prognosis.
  • Lapatinib targets both EGFR (ErbB1) and HER2 (ErbB2) tyrosine kinases.

Purpose of the Study:

  • To evaluate the efficacy and safety of lapatinib in HER2-positive breast cancer.
  • To explore lapatinib's potential in trastuzumab-resistant and advanced/metastatic settings.

Main Methods:

  • Preclinical studies assessed lapatinib's activity in trastuzumab-resistant cell lines and synergistic effects with trastuzumab.
  • Phase I trials evaluated safety and tolerability.
  • A Phase III trial compared lapatinib plus capecitabine versus capecitabine alone in previously treated advanced/metastatic breast cancer.

Main Results:

  • Lapatinib demonstrated activity in trastuzumab-resistant models and synergistic effects with trastuzumab.
  • Phase I trials showed good tolerability with mild side effects and low cardiotoxicity.
  • The Phase III trial showed nearly doubled progression-free survival (8.4 vs. 4.1 months) for the lapatinib-capecitabine combination, with similar overall survival (15.6 vs. 15.4 months).

Conclusions:

  • Lapatinib is a well-tolerated dual tyrosine kinase inhibitor with demonstrated efficacy in HER2-positive advanced/metastatic breast cancer.
  • Combination therapy with capecitabine significantly improves progression-free survival in heavily pretreated patients.
  • Ongoing trials are investigating lapatinib in various combinations and settings for breast cancer treatment.

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...